ContributorsPublishersAdvertisers

Pembrolizumab Plus Chemotherapy Represents New SOC for Esophageal Cancer/ GEJ Adenocarcinoma

targetedonc.com
 2022-01-22

Cover picture for the articleAccording to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit. In patients with locally advanced and metastatic esophageal cancer—including gastroesophageal junction (GEJ) adenocarcinoma treated in the KEYNOTE-590 study (NCT03189719, first-line pembrolizumab (Keytruda) plus chemotherapy continued...

www.targetedonc.com

Comments / 0

Comments / 0